This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Abbas Z., Yakoob J., Jafri W., Ahmad Z., Azam Z., Usman M.W., Shamim S., Islam M.: Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: a randomized trial. J. Gastroenterol. Hepatol. 26, 630–639 (2014)AbbasZ.YakoobJ.JafriW.AhmadZ.AzamZ.UsmanM.W.ShamimS.IslamM.Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: a randomized trialJ. Gastroenterol. Hepatol.26630639201410.1097/MEG.000000000000009424722560Search in Google Scholar
Agbaje M., Begum R.H., Oyekunle M.A., Ojo O.E., Adenubi O.T.: Evolution of Salmonella nomenclature: a critical note. F. Microbiol. 56, 497–503 (2011)AgbajeM.BegumR.H.OyekunleM.A.OjoO.E.AdenubiO.T.Evolution of Salmonella nomenclature: a critical noteF. Microbiol.56497503201110.1007/s12223-011-0075-422052214Search in Google Scholar
Arslan S., Erbas M., Tontul I., Topuz A.: Microencapsulation of probiotic Saccharomyces cerevisiae var. boulardii with different wall materials by spray drying. LWT-Food Sci Technol. 63, 685–690 (2015)ArslanS.ErbasM.TontulI.TopuzA.Microencapsulation of probiotic Saccharomyces cerevisiae var. boulardii with different wall materials by spray dryingLWT-Food Sci Technol.63685690201510.1016/j.lwt.2015.03.034Search in Google Scholar
Astó E., Méndez I., Audivert S., Farran-Codina A., Espadaler J.: The Efficacy of probiotics, prebiotic inulin-type fructans, and synbiotics in human ulcerative colitis: a systematic review and meta-analysis. Nutrients, 11, 293 (2019)AstóE.MéndezI.AudivertS.Farran-CodinaA.EspadalerJ.The Efficacy of probiotics, prebiotic inulin-type fructans, and synbiotics in human ulcerative colitis: a systematic review and meta-analysisNutrients11293201910.3390/nu11020293641253930704039Search in Google Scholar
Bafutto M., Almeida J.R.D., Leite N.V., Costa M.B.G., Oliveira E.C.D., Resende-Filho J.: Treatment of diarrhea-predominant irritable bowel syndrome with mesalazine and/or Saccharomyces boulardii. Arq Gastroenterol, 50, 304–309 (2013)BafuttoM.AlmeidaJ.R.D.LeiteN.V.CostaM.B.G.OliveiraE.C.D.Resende-FilhoJ.Treatment of diarrhea-predominant irritable bowel syndrome with mesalazine and/or Saccharomyces boulardiiArq Gastroenterol50304309201310.1590/S0004-2803201300040001224474234Search in Google Scholar
Barbara G., Cremon C., Azpiroz F.: Probiotics in irritable bowel syndrome: Where are we? Neurogastroenterol. 30, e13513 (2018)BarbaraG.CremonC.AzpirozF.Probiotics in irritable bowel syndrome: Where are we?Neurogastroenterol.30e13513201810.1111/nmo.1351330460770Search in Google Scholar
Boirivant M., Strober W.: The mechanism of action of probiotics. Curr Opin Gastroenterol. 23, 679–692 (2007)BoirivantM.StroberW.The mechanism of action of probioticsCurr Opin Gastroenterol.23679692200710.1097/MOG.0b013e3282f0cffc17906447Search in Google Scholar
Brun P., Scarpa M., Marchiori C., Sarasin G., Caputi V., Porzionato A., Giron M.C., Palù G., Castagliuolo I.: Saccharomyces boulardii CNCM I-745 supplementation reduces gastrointestinal dysfunction in an animal model of IBS. PloS One, 12, e0181863 (2017)BrunP.ScarpaM.MarchioriC.SarasinG.CaputiV.PorzionatoA.GironM.C.PalùG.CastagliuoloI.Saccharomyces boulardii CNCM I-745 supplementation reduces gastrointestinal dysfunction in an animal model of IBSPloS One12e0181863201710.1371/journal.pone.0181863552184228732069Search in Google Scholar
Buts J.P.: Twenty-five years of research on Saccharomyces boulardii trophic effects: updates and perspectives. Dig. Dis. Sci. 54, 15–18 (2009)ButsJ.P.Twenty-five years of research on Saccharomyces boulardii trophic effects: updates and perspectivesDig. Dis. Sci.541518200910.1007/s10620-008-0322-y18528758Search in Google Scholar
Buts J.P., De Keyser N.: Effects of Saccharomyces boulardii on intestinal mucosa. Dig. Dis. Sci. 51, 1485–1492 (2006)ButsJ.P.De KeyserN.Effects of Saccharomyces boulardii on intestinal mucosaDig. Dis. Sci.5114851492200610.1007/s10620-005-9016-x16838119Search in Google Scholar
Buts J.P., De Keyser N.: Transduction pathways regulating the trophic effects of Saccharomyces boulardii in rat intestinal mucosa. Scand. J. Gastroenterol. 45, 175–185 (2010)ButsJ.P.De KeyserN.Transduction pathways regulating the trophic effects of Saccharomyces boulardii in rat intestinal mucosaScand. J. Gastroenterol.45175185201010.1038/npre.2009.3061.1Search in Google Scholar
Canavan C., West J., Card T.: The epidemiology of irritable bowel syndrome. Clin. Epidemiol. 6, 71 (2014)CanavanC.WestJ.CardT.The epidemiology of irritable bowel syndromeClin. Epidemiol.671201410.2147/CLEP.S40245392108324523597Search in Google Scholar
Carter D., Beer-Gabel M., Tzur D., Levy G., Derazne E., Novis B., Afek A.: Predictive factors for the diagnosis of irritable bowel syndrome in a large cohort of 440,822 young adults. J. Clin. Gastroenterol. 49, 300–305 (2015)CarterD.Beer-GabelM.TzurD.LevyG.DerazneE.NovisB.AfekA.Predictive factors for the diagnosis of irritable bowel syndrome in a large cohort of 440,822 young adultsJ. Clin. Gastroenterol.49300305201510.1097/MCG.000000000000011424637731Search in Google Scholar
Chen X., Kokkotou E.G., Mustafa N., Bhaskar K.R., Sougioultzis S., O’Brien M., Pothoulakis C., Kelly C.P.: Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritis. J. Biol. Chem. 281, 24449–24454 (2006)ChenX.KokkotouE.G.MustafaN.BhaskarK.R.SougioultzisS.O’BrienM.PothoulakisC.KellyC.P.Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritisJ. Biol. Chem.2812444924454200610.1074/jbc.M60520020016816386Search in Google Scholar
Choi C.H., Jo S.Y., Park H.J., Chang S.K., Byeon J.S., Myung S.J.: A randomized, double-blind, placebo-controlled multicenter trial of Saccharomyces boulardii in irritable bowel syndrome: effect on quality of life. J. Clin. Gastroenterol. 45, 679–683 (2011)ChoiC.H.JoS.Y.ParkH.J.ChangS.K.ByeonJ.S.MyungS.J.A randomized, double-blind, placebo-controlled multicenter trial of Saccharomyces boulardii in irritable bowel syndrome: effect on quality of lifeJ. Clin. Gastroenterol.45679683201110.1097/MCG.0b013e318204593e21301358Search in Google Scholar
Ciorba M.A.: A gastroenterologist’s guide to probiotics. J. Gastroenterol. Hepatol. 10, 960–968 (2012)CiorbaM.A.A gastroenterologist’s guide to probioticsJ. Gastroenterol. Hepatol.10960968201210.1016/j.cgh.2012.03.024342431122504002Search in Google Scholar
Cotesta D., Caliumi C., Alò P., Petramala L., Reale M.G., Masciangelo R., Signore A., Cianci R., D’Erasmo E., Letizia C.: High plasma levels of human chromogranin A and adrenomedullin in patients with pheochromocytoma. Tumori, 91, 53–58 (2005)CotestaD.CaliumiC.AlòP.PetramalaL.RealeM.G.MasciangeloR.SignoreA.CianciR.D’ErasmoE.LetiziaC.High plasma levels of human chromogranin A and adrenomedullin in patients with pheochromocytomaTumori915358200510.1177/030089160509100110Search in Google Scholar
Czerucka D., Piche T., Rampal P.: Yeast as probiotics – Saccharomyces boulardii. Aliment. Pharmacol. Ther. 26, 767–778 (2007)CzeruckaD.PicheT.RampalP.Yeast as probiotics – Saccharomyces boulardiiAliment. Pharmacol. Ther.26767778200710.1111/j.1365-2036.2007.03442.x17767461Search in Google Scholar
Czerucka D., Rampal P.: Effect of Saccharomyces boulardii on cAMP-and Ca2+–dependent Cl-secretion in T84 cells. Dig. Dis. Sci. 44, 2359–2368 (1999)CzeruckaD.RampalP.Effect of Saccharomyces boulardii on cAMP-and Ca2+–dependent Cl-secretion in T84 cellsDig. Dis. Sci.4423592368199910.1023/A:1026689628136Search in Google Scholar
Dai C., Zheng C.Q., Jiang M., Ma X.Y., Jiang L.J.: Probiotics and irritable bowel syndrome. World J. Gastroenterol. 19, 5973 (2013)DaiC.ZhengC.Q.JiangM.MaX.Y.JiangL.J.Probiotics and irritable bowel syndromeWorld J. Gastroenterol.195973201310.3748/wjg.v19.i36.5973378561824106397Search in Google Scholar
Dalmasso G., Cottrez F., Imbert V., Lagadec P., Peyron J.F., Rampal P., Czerucka D., Groux H.: Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. Gastroenterology, 131, 1812–1825 (2006)DalmassoG.CottrezF.ImbertV.LagadecP.PeyronJ.F.RampalP.CzeruckaD.GrouxH.Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodesGastroenterology13118121825200610.1053/j.gastro.2006.10.001Search in Google Scholar
de Chambrun G.P., Neut C., Chau A., Cazaubiel M., Pelerin F., Justen P., Desreumaux P.: A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome. Dig. Liver Dis. 47, 119–124 (2015)de ChambrunG.P.NeutC.ChauA.CazaubielM.PelerinF.JustenP.DesreumauxP.A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndromeDig. Liver Dis.47119124201510.1016/j.dld.2014.11.007Search in Google Scholar
Dogan B., Una S.: Kruis scoring system and Manning’s criteria in diagnosis of irritable bowel syndrome: is it better to use combined? Acta Gastro-Emerologica Belgica, 59 (1996)DoganB.UnaS.Kruis scoring system and Manning’s criteria in diagnosis of irritable bowel syndrome: is it better to use combined?Acta Gastro-Emerologica Belgica591996Search in Google Scholar
Drossman D.A.: Functional gastrointestinal disorders: history, pathophysiology, clinical features, and Rome IV. Gastroenterology, 150, 1262–1279 (2016)DrossmanD.A.Functional gastrointestinal disorders: history, pathophysiology, clinical features, and Rome IVGastroenterology15012621279201610.1053/j.gastro.2016.02.032Search in Google Scholar
Drouault-Holowacz S., Bieuvelet S., Burckel A., Cazaubiel M., Dray X., Marteau P.: A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. Gastroen. Clin. Biol. 32, 147–152 (2008)Drouault-HolowaczS.BieuveletS.BurckelA.CazaubielM.DrayX.MarteauP.A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndromeGastroen. Clin. Biol.32147152200810.1016/j.gcb.2007.06.001Search in Google Scholar
Du L.P., Hao R.X., Xiao D.G., Guo L.L., Gai W.D.: Research on the Characteristics and Culture Conditions of Saccharomyces boulardii. Adv. Mater. Res. 343, 594–598 (2012)DuL.P.HaoR.X.XiaoD.G.GuoL.L.GaiW.D.Research on the Characteristics and Culture Conditions of Saccharomyces boulardiiAdv. Mater. Res.3435945982012Search in Google Scholar
Elhasi T., Blomberg A.: Integrins in disguise-mechanosensors in Saccharomyces cerevisiae as functional integrin analogues. Microb. Cell, 6, 335 (2019)ElhasiT.BlombergA.Integrins in disguise-mechanosensors in Saccharomyces cerevisiae as functional integrin analoguesMicrob. Cell6335201910.15698/mic2019.08.686Search in Google Scholar
El-Salhy M., Seim I., Chopin L., Gundersen D., Hatlebakk J. G., Hausken T.: Irritable bowel syndrome: the role of gut neuroendocrine peptides. Front. Biosci. 4, 2783–2800 (2012)El-SalhyM.SeimI.ChopinL.GundersenD.HatlebakkJ. G.HauskenT.Irritable bowel syndrome: the role of gut neuroendocrine peptidesFront. Biosci.427832800201210.2741/e583Search in Google Scholar
Fond G., Loundou A., Hamdani N., Boukouaci W., Dargel A., Oliveira J., Roger M., Tamouza R., Leboyer M., Boyer L.: Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis. Eur. Arch. Psychiatry Clin. Neurosci. 264, 651–660 (2014)FondG.LoundouA.HamdaniN.BoukouaciW.DargelA.OliveiraJ.RogerM.TamouzaR.LeboyerM.BoyerL.Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysisEur. Arch. Psychiatry Clin. Neurosci.264651660201410.1007/s00406-014-0502-zSearch in Google Scholar
Gogineni V.K., Morrow L.E., Gregory P.J., Malesker M.A.: Probiotics: history and evolution. J. Anc. Dis. Prev. Rem. DOI: 10.4172/2329-8731.1000107 (2013)GogineniV.K.MorrowL.E.GregoryP.J.MaleskerM.A.Probiotics: history and evolutionJ. Anc. Dis. Prev. Rem.10.4172/2329-8731.10001072013Open DOISearch in Google Scholar
Gu Y., Zhou G., Liu X., Wang B., Cao H.: 105–Saccharomyces Boulardii, a Yeast Probiotic, Regulates Serotonin Transporter in the Intestine. Gastroenterology, 156, 26 (2019)GuY.ZhouG.LiuX.WangB.CaoH.105–Saccharomyces Boulardii, a Yeast Probiotic, Regulates Serotonin Transporter in the IntestineGastroenterology15626201910.1016/S0016-5085(19)36839-8Search in Google Scholar
Hemaiswarya S., Raja R., Ravikumar R., Carvalho I.S.: Mechanism of action of probiotics. Braz. Arch. Biol. Technol. 56, 113–119 (2013)HemaiswaryaS.RajaR.RavikumarR.CarvalhoI.S.Mechanism of action of probioticsBraz. Arch. Biol. Technol.56113119201310.1590/S1516-89132013000100015Search in Google Scholar
Homayouni A., Payahoo L., Azizi A.: Effects of probiotics on lipid profile: A review. Am. J. Food Technol. 7, 251–265 (2012)HomayouniA.PayahooL.AziziA.Effects of probiotics on lipid profile: A reviewAm. J. Food Technol.7251265201210.3923/ajft.2012.251.265Search in Google Scholar
Hoveyda N., Heneghan C., Mahtani K.R., Perera R., Roberts N., Glaszio P.: A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol, 9, 15 (2009)HoveydaN.HeneghanC.MahtaniK.R.PereraR.RobertsN.GlaszioP.A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndromeBMC Gastroenterol915200910.1186/1471-230X-9-15Search in Google Scholar
Index Fungorum: Saccharomyces, http://www.indexfungorum.org/names/NamesRecord.asp?RecordID=4813 (05.02.2020)Index FungorumSaccharomyceshttp://www.indexfungorum.org/names/NamesRecord.asp?RecordID=4813 (05.02.2020)Search in Google Scholar
Intech Open: Probiotics, http://dx.doi.org/10.5772/3444 (05.02.2020)Intech OpenProbioticshttp://dx.doi.org/10.5772/3444 (05.02.2020)10.5772/3444Search in Google Scholar
Janda J.M., Abbott S. L.: The genus Aeromonas: taxonomy, pathogenicity, and infection. Clin. Microbiol. Rev. 23, 35–73 (2010)JandaJ.M.AbbottS. L.The genus Aeromonas: taxonomy, pathogenicity, and infectionClin. Microbiol. Rev.233573201010.1128/CMR.00039-09Search in Google Scholar
Jiménez M.B.: Treatment of irritable bowel syndrome with probiotics. An etiopathogenic approach at last. Rev. Esp. Enferm. Dig. 101, 553–564 (2009)JiménezM.B.Treatment of irritable bowel syndrome with probiotics. An etiopathogenic approach at lastRev. Esp. Enferm. Dig.1015535642009Search in Google Scholar
Karantanos T., Markoutsaki T., Gazouli M., Anagnou N.P., Karamanolis D.G.: Current insights in to the pathophysiology of Irritable Bowel Syndrome. Gut Pathog. 2, 3 (2010)KarantanosT.MarkoutsakiT.GazouliM.AnagnouN.P.KaramanolisD.G.Current insights in to the pathophysiology of Irritable Bowel SyndromeGut Pathog.23201010.1186/1757-4749-2-3Search in Google Scholar
Kechagia M., Basoulis D., Konstantopoulou S., Dimitriadi D., Gyftopoulou K., Skarmoutsou N., Fakiri E.M.: Health benefits of probiotics: a review. ISRN Nutr. 2013, DOI: 10.5402/2013/481651 (2013)KechagiaM.BasoulisD.KonstantopoulouS.DimitriadiD.GyftopoulouK.SkarmoutsouN.FakiriE.M.Health benefits of probiotics: a reviewISRN Nutr.201310.5402/2013/4816512013Open DOISearch in Google Scholar
Kelesidis T., Pothoulakis C.: Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. Therap. Adv. Gastroenterol. 5, 111–125 (2012)KelesidisT.PothoulakisC.Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disordersTherap. Adv. Gastroenterol.5111125201210.1177/1756283X11428502Search in Google Scholar
Kerry R.G., Patra J.K., Gouda S., Park Y., Shin H. S., Das G.: Benefaction of probiotics for human health: A review. J. Food Drug. Anal. 26, 927–939 (2018)KerryR.G.PatraJ.K.GoudaS.ParkY.ShinH. S.DasG.Benefaction of probiotics for human health: A reviewJ. Food Drug. Anal.26927939201810.1016/j.jfda.2018.01.002Search in Google Scholar
Krogsgaard L.R., Engsbro A.L., Jones M.P., Bytzer P.: The epidemiology of irritable bowel syndrome: Symptom development over a 3-year period in Denmark. A prospective, populationbased cohort study. Neurogastroenterol. Motil. 29, (2017)KrogsgaardL.R.EngsbroA.L.JonesM.P.BytzerP.The epidemiology of irritable bowel syndrome: Symptom development over a 3-year period in Denmark. A prospective, populationbased cohort studyNeurogastroenterol. Motil.29201710.1111/nmo.12986Search in Google Scholar
Kruis W., Thieme C.H., Weinzierl M., Schuessler P., Holl J., Paulus W.: A diagnostic score for the irritable bowel syndrome. Its value in the exlusion of organic disease. Gastroenterology, 87, 1–7 (1984)KruisW.ThiemeC.H.WeinzierlM.SchuesslerP.HollJ.PaulusW.A diagnostic score for the irritable bowel syndrome. Its value in the exlusion of organic diseaseGastroenterology8717198410.1016/0016-5085(84)90119-7Search in Google Scholar
Lee B.J., Bak Y.T.: Irritable bowel syndrome, gut microbiota and probiotics. J. Neurogastroenterol. Motil. 17, 252 (2011)LeeB.J.BakY.T.Irritable bowel syndrome, gut microbiota and probioticsJ. Neurogastroenterol. Motil.17252201110.5056/jnm.2011.17.3.252315506121860817Search in Google Scholar
Leventogiannis K., Gkolfakis P., Spithakis G., Tsatali A., Pistiki A., Sioulas A., Giamarellos-Bourboulis E.J., Triantafyllou K.: Effect of a preparation of four probiotics on symptoms of patients with irritable bowel syndrome: association with intestinal bacterial overgrowth. Probiotics Antimicrob. Proteins, 11, 627–634 (2019)LeventogiannisK.GkolfakisP.SpithakisG.TsataliA.PistikiA.SioulasA.Giamarellos-BourboulisE.J.TriantafyllouK.Effect of a preparation of four probiotics on symptoms of patients with irritable bowel syndrome: association with intestinal bacterial overgrowthProbiotics Antimicrob. Proteins11627634201910.1007/s12602-018-9401-3654157529508268Search in Google Scholar
Manning A.P., Thompson W.G., Heaton K.W., Morris A.F.: Towards positive diagnosis of the irritable bowel. Br. Med. J. 2, 653–654 (1978)ManningA.P.ThompsonW.G.HeatonK.W.MorrisA.F.Towards positive diagnosis of the irritable bowelBr. Med. J.2653654197810.1136/bmj.2.6138.6531607467698649Search in Google Scholar
McFarland L.V.: Common organisms and probiotics: Saccharomyces boulardii. The Microbiota in Gastrointestinal Pathophysiology, Academic Press, 145–164 (2017)McFarlandL.V.Common organisms and probiotics: Saccharomyces boulardiiThe Microbiota in Gastrointestinal PathophysiologyAcademic Press145164201710.1016/B978-0-12-804024-9.00018-5Search in Google Scholar
McFarland L.V.: Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J. Gastroenterol, 16, 2202 (2010)McFarlandL.V.Systematic review and meta-analysis of Saccharomyces boulardii in adult patientsWorld J. Gastroenterol162202201010.3748/wjg.v16.i18.2202286821320458757Search in Google Scholar
Méabed E.M., Abdelhafez D.N., Abdelaliem Y.F.: Saccharomyces boulardii inhibits the expression of pro-inflammatory cytokines and inducible nitric oxide synthase genes in the colonic mucosa of rats experimentally-infected with Blastocystis subtype-3 cysts. Parasitology, DOI: 10.1017/S0031182019000696 (2019)MéabedE.M.AbdelhafezD.N.AbdelaliemY.F.Saccharomyces boulardii inhibits the expression of pro-inflammatory cytokines and inducible nitric oxide synthase genes in the colonic mucosa of rats experimentally-infected with Blastocystis subtype-3 cystsParasitology10.1017/S0031182019000696201931109390Open DOISearch in Google Scholar
More M.I., Swidsinski A.: Saccharomyces boulardii CNCM I-745 supports regeneration of the intestinal microbiota after diarrheic dysbiosis – a review. Clin. Exp. Gastroenterol. 8, 237 (2015)MoreM.I.SwidsinskiA.Saccharomyces boulardii CNCM I-745 supports regeneration of the intestinal microbiota after diarrheic dysbiosis – a reviewClin. Exp. Gastroenterol.8237201510.2147/CEG.S85574454255226316791Search in Google Scholar
Mulak A., Smereka A., Paradowski L.: Nowości i modyfikacje w Kryteriach Rzymskich IV. Gastroenterologia Kliniczna. Postępy i Standardy, 8 (2016)MulakA.SmerekaA.ParadowskiL.Nowości i modyfikacje w Kryteriach Rzymskich IVGastroenterologia Kliniczna. Postępy i Standardy82016Search in Google Scholar
Nikou G.C., Lygidakis N.J., Toubanakis C., Pavlatos S., Tseleni-Balafouta S., Giannatou E., Mallas E., Safioleas M.: Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues. Hepato-Gastroenterology, 52, 731–741 (2005)NikouG.C.LygidakisN.J.ToubanakisC.PavlatosS.Tseleni-BalafoutaS.GiannatouE.MallasE.SafioleasM.Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analoguesHepato-Gastroenterology527317412005Search in Google Scholar
Ng S.C., Hart A.L., Kamm M.A., Stagg A.J., Knight S.C.: Mechanisms of action of probiotics: recent advances. Inflamm. Bowel Dis. 15, 300–310 (2008)NgS.C.HartA.L.KammM.A.StaggA.J.KnightS.C.Mechanisms of action of probiotics: recent advancesInflamm. Bowel Dis.15300310200810.1002/ibd.2060218626975Search in Google Scholar
Oak S.J., Jha R.: The effects of probiotics in lactose intolerance: a systematic review. Crit Rev. Food Sci. Nutr. 59, 1675–1683 (2019)OakS.J.JhaR.The effects of probiotics in lactose intolerance: a systematic reviewCrit Rev. Food Sci. Nutr.5916751683201910.1080/10408398.2018.142597729425071Search in Google Scholar
Oelschlaeger T.A.: Mechanisms of probiotic actions – a review. Int. J. Med. Microbiol. 300, 57–62 (2010)OelschlaegerT.A.Mechanisms of probiotic actions – a reviewInt. J. Med. Microbiol.3005762201010.1016/j.ijmm.2009.08.00519783474Search in Google Scholar
Parkes G.C., Sanderson J.D., Whelan K.: Treating irritable bowel syndrome with probiotics: the evidence. Proc. Nutr. Soc. 69, 187–194 (2010)ParkesG.C.SandersonJ.D.WhelanK.Treating irritable bowel syndrome with probiotics: the evidenceProc. Nutr. Soc.69187194201010.1017/S002966511000011X20236566Search in Google Scholar
Pothoulakis C.: Anti-inflammatory mechanisms of action of Saccharomyces boulardii. Aliment Pharmacol. Ther. 30, 826–833 (2009)PothoulakisC.Anti-inflammatory mechanisms of action of Saccharomyces boulardiiAliment Pharmacol. Ther.30826833200910.1111/j.1365-2036.2009.04102.x276162719706150Search in Google Scholar
Qin H.Y., Cheng C.W., Tang X.D., Bian Z.X.: Impact of psychological stress on irritable bowel syndrome. World J. Gastroenterol. 20, 14126 (2014)QinH.Y.ChengC.W.TangX.D.BianZ.X.Impact of psychological stress on irritable bowel syndromeWorld J. Gastroenterol.2014126201410.3748/wjg.v20.i39.14126420234325339801Search in Google Scholar
Quigley E.M.: Prebiotics and probiotics; modifying and mining the microbiota. Pharmacol. Res. 61, 213–218 (2010)QuigleyE.M.Prebiotics and probiotics; modifying and mining the microbiotaPharmacol. Res.61213218201010.1016/j.phrs.2010.01.00420080184Search in Google Scholar
Rima H., Steve L., Ismail F.: Antimicrobial and probiotic properties of yeasts: from fundamental to novel applications. Front. Microbiol. 3, 421 (2012)RimaH.SteveL.IsmailF.Antimicrobial and probiotic properties of yeasts: from fundamental to novel applicationsFront. Microbiol.3421201210.3389/fmicb.2012.00421352588123267352Search in Google Scholar
Ringel Y., Quigley E.M., Lin H.C.: Using probiotics in gastrointestinal disorders. Am. J. Gastroenterol. Suppl. 1, 34, (2012)RingelY.QuigleyE.M.LinH.C.Using probiotics in gastrointestinal disordersAm. J. Gastroenterol. Suppl.134201210.1038/ajgsup.2012.7Search in Google Scholar
Ringel Y., Ringel-Kulka T.: The rationale and clinical effectiveness of probiotics in irritable bowel syndrome. J. Clin. Gastroenterol. 45, 145–148 (2011)RingelY.Ringel-KulkaT.The rationale and clinical effectiveness of probiotics in irritable bowel syndromeJ. Clin. Gastroenterol.45145148201110.1097/MCG.0b013e31822d32d321992954Search in Google Scholar
Rodrigues A.C.P., Cara D.C., Fretez S.H.G.G., Cunha F.Q., Vieira E.C., Nicoli J.R., Vieira L.Q.: Saccharomyces boulardii stimulates sIgA production and the phagocytic system of gnotobiotic mice. J. Appl. Microbiol. 89, 404–414 (2000)RodriguesA.C.P.CaraD.C.FretezS.H.G.G.CunhaF.Q.VieiraE.C.NicoliJ.R.VieiraL.Q.Saccharomyces boulardii stimulates sIgA production and the phagocytic system of gnotobiotic miceJ. Appl. Microbiol.89404414200010.1046/j.1365-2672.2000.01128.x11021572Search in Google Scholar
Schmulson M.J., Drossman D.A.: What is new in Rome IV. J. Neurogastroenterol. Motil. 23, 151 (2017)SchmulsonM.J.DrossmanD.A.What is new in Rome IVJ. Neurogastroenterol. Motil.23151201710.5056/jnm16214538311028274109Search in Google Scholar
Sherman P.M., Ossa J.C., Johnson-Henry K.: Unraveling mechanisms of action of probiotics. Nutr. Clin. Pract. 24, 10–14 (2009)ShermanP.M.OssaJ.C.Johnson-HenryK.Unraveling mechanisms of action of probioticsNutr. Clin. Pract.241014200910.1177/088453360832923119244144Search in Google Scholar
Soyturk M., Saygili S.M., Baskin H., Sagol O., Yilmaz O., Saygili F., Akpinar H.: Effectiveness of Saccharomyces boulardii in a rat model of colitis. World J. Gastroenterol. 18, 6452 (2012)SoyturkM.SaygiliS.M.BaskinH.SagolO.YilmazO.SaygiliF.AkpinarH.Effectiveness of Saccharomyces boulardii in a rat model of colitisWorld J. Gastroenterol.186452201210.3748/wjg.v18.i44.6452350864023197891Search in Google Scholar
Stier H., Bischoff S.C.: Influence of Saccharomyces boulardii CNCM I-745on the gut-associated immune system. Clin. Exp. Gastroenterol. 9, 269 (2016)StierH.BischoffS.C.Influence of Saccharomyces boulardii CNCM I-745on the gut-associated immune systemClin. Exp. Gastroenterol.9269201610.2147/CEG.S111003502794927695355Search in Google Scholar
Szajewska H., Skorka A., Dylag M.: Meta-analysis: Saccharomyces boulardii for treating acute diarrhoea in children. Aliment Pharmacol. Ther. 25, 257–264 (2007)SzajewskaH.SkorkaA.DylagM.Meta-analysis: Saccharomyces boulardii for treating acute diarrhoea in childrenAliment Pharmacol. Ther.25257264200710.1111/j.1365-2036.2006.03202.x17269987Search in Google Scholar
Terciolo C., Andre F. i wsp.: Saccharomyces boulardii CNCM I-745 restores intestinal barrier integrity by regulation of E-cadherin recycling. J. Crohns Colitis, 11, 999–1010 (2017)TercioloC.AndreF.i wsp.Saccharomyces boulardii CNCM I-745 restores intestinal barrier integrity by regulation of E-cadherin recyclingJ. Crohns Colitis119991010201710.1093/ecco-jcc/jjx03028333335Search in Google Scholar
Terciolo C., Dapoigny M., Andre F.: Beneficial effects of Saccharomyces boulardii CNCM I-745 on clinical disorders associated with intestinal barrier disruption. Clin. Exp. Gastroenterol. 12, 67 (2019)TercioloC.DapoignyM.AndreF.Beneficial effects of Saccharomyces boulardii CNCM I-745 on clinical disorders associated with intestinal barrier disruptionClin. Exp. Gastroenterol.1267201910.2147/CEG.S181590637511530804678Search in Google Scholar
Tiago F.D.C.P., Martins F.D.S., Souza E.L.S., Pimenta P.F.P., Araújo H.R.C., Castro I.D.M., Brandão R.L., Nicoli J.R.: Adhesion to the yeast cell surface as a mechanism for trapping pathogenic bacteria by Saccharomyces probiotics. J. Med. Microbiol. 61, 1194–1207 (2012)TiagoF.D.C.P.MartinsF.D.S.SouzaE.L.S.PimentaP.F.P.AraújoH.R.C.CastroI.D.M.BrandãoR.L.NicoliJ.R.Adhesion to the yeast cell surface as a mechanism for trapping pathogenic bacteria by Saccharomyces probioticsJ. Med. Microbiol.6111941207201210.1099/jmm.0.042283-022580913Search in Google Scholar
Whelan K.: Probiotics and prebiotics in the management of irritable bowel syndrome: a review of recent clinical trials and systematic reviews. Curr. Opin. Clin. Nutr. Metab. Care, 14, 581–587 (2011)WhelanK.Probiotics and prebiotics in the management of irritable bowel syndrome: a review of recent clinical trials and systematic reviewsCurr. Opin. Clin. Nutr. Metab. Care14581587201110.1097/MCO.0b013e32834b808221892075Search in Google Scholar
Whelan K., Quigley E.M.: Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease. Curr. Opin. Gastroenterol. 29, 184–189 (2013)WhelanK.QuigleyE.M.Probiotics in the management of irritable bowel syndrome and inflammatory bowel diseaseCurr. Opin. Gastroenterol.29184189201310.1097/MOG.0b013e32835d7bba23286925Search in Google Scholar
Wu J.T., Erickson A.J., Tsao K.C., Wu T.L., Sun C.F.: Elevated serum chromogranin A is detectable in patients with carcinomas at advanced disease stages. Ann. Clin. Lab Sci. 30, 175–178 (2000)WuJ.T.EricksonA.J.TsaoK.C.WuT.L.SunC.F.Elevated serum chromogranin A is detectable in patients with carcinomas at advanced disease stagesAnn. Clin. Lab Sci.301751782000Search in Google Scholar
